Making your mind up

Are all PARP inhibitors the same?

September 10, 2022

The long and winding road to success

An emerging new and highly selective oncogenic target

June 30, 2022

A journey that never ends

Can NK cells help checkpoint blockade work more effectively?

April 27, 2022

Discovering novel oncogenic targets

Finding new synthetic lethal targets to induce more potent cell death and improve outcomes

April 8, 2022

How – and when – should people with early stage breast cancer be treated with a PARP inhibitor?

Is the OlympiA trial groundbreaking for early stage breast cancer?

March 16, 2022

Pulling a rabbit out of a hat

Surprises galore in the unveiling of the PARP data in 1L mCRPC!

February 21, 2022

Learning from what patients tumours are telling us

Cracking the tumour code

February 4, 2022

Finding achilles heels to tackle cancer head on

Exploring new approaches to targeting cancer

January 20, 2022
Washington DC in Fall

SITC21 – What to Watch out for

SITC 2021 Preview

October 22, 2021

Endless DDR changes and how we are going beyond PARP inhibitors

A detailed look at Repare's ATR inhibitor data from the TRIPLE meeting

October 15, 2021

Coming back full circle

Can a genomic signature help select patients more accurately for DDR therapies?

August 26, 2021

Sorting signals from the noise

PARP plus IO and IO combos are becoming all the rage, what can we learn from early signals?

March 5, 2019

Are AI and machine learning alive or dead in oncology?

How can AI and ML speed up or improve our drug discovery efforts in oncology R&D?

June 15, 2021

An in-depth look at OLYMPIAD in HER2 negative breast cancer

Olaparib is the first PARP to demonstrate a clinical benefit in HER2- breast cancer - what do KOLs really think?

June 12, 2017

Novel DDR combinations and regimens that could make a difference

Latest preclinical and clinical news and readouts as well as forthcoming trial presentations to look forward to in the DDR space

August 16, 2019

Which early phase agents look promising – or not – ASCO21?

New product development and early phase anti-cancer agents have been very much a focus on BSB (and PSB…

June 6, 2021

Is olaparib scaling new heights in OlympiA?

PARP inhibitors move into the adjuvant setting at long last? Say it ain't so!

June 3, 2021

ASCO21 Off the Beaten Track Part 2

A look at some hidden gems in the ASCO program and what it all means in terms of the science.

May 27, 2021

When PARP and immunotherapy worlds collide

New research is emerging which may have an impact on future trial designs as well as combination partners and even different tumour types.

May 12, 2021

The future of breast cancer research

Some key learnings from the ESMO Breast Cancer meeting held last week

May 10, 2021

Tooting the DDR horn

Bridging the DDR gap from AACR to ASCO

May 7, 2021

AACR21 Preview 5 Promising new developments in the PARP field and beyond

What's hot on the DDR front and PARP inhibitor space at AACR21?

March 25, 2021

AACR21 Preview 3 Novel and cool approaches emerging in oncology pipelines

Emerging areas in cool new science around targeted therapies

March 18, 2021

Finding success in hard to treat breast cancers

Post SABCS analysis of a key topic and cancer driver

December 15, 2020

Notes from a small island

new approaches to applying translational research to the clinic in oncology R&D

November 3, 2020

TRIPLE highlights and lowlights in Developmental Therapeutics

The trials and tribulations of targeted agents in developmental therapeutics

October 25, 2020

A contrarian view of key cancer trial results

Winners, losers and risers... who goes where in the final analysis?

October 8, 2020

A phoenix rises from the ashes

A look at one oncology biotech company's early pipeline and how it fits in with the emerging landscape

September 23, 2020

Important learnings from ESMO20

Surprising new developments in early stage breast and metastatic prostate cancers

September 21, 2020

ESMO20 Preview 4 – Targeted therapies to watch out for

What to watch out for this weekend in targeted therapies and early stage new product development

September 17, 2020

Flying high in the DDR oncology niche

New developments in the DDR niche suggest a whole new approach to tackling solid tumours beyond women's cancers, pancreatic and prostate cancer might be feasible.

May 5, 2020

Novel anti-cancer agents to watch out for

A look at five novel anti-cancer agents in early R&D pipelines and what we can learn from their experiences

April 30, 2020

AACR20 – Ten New Directions in Early Cancer Drug Development

Ten intriguing novel agents in early development to watch out for

April 23, 2020

PARP inhibition in metastatic prostate cancer

What can we learn from the phase 2 trials with PARP inhibitors in mCRPC? Quite a lot, it would seem...

October 9, 2019

Crossing the Rubicon

Insights from a US KOL on the phase 3 PROfound trial exploring olaparib in mCRPC

October 8, 2019

ESMO19 Day 4 Highlights including the PROfound trial in advanced prostate cancer

Highlights from the PROfound trial in advanced prostate cancer and other stories of interest

September 30, 2019

ESMO19 Day 3 Highlights and Commentary

Key findings and commentary on the third day of ESMO

September 29, 2019

Highlights of Day 2 at ASCO19

Insights from Day 2 of ASCO19, plus a look at what to expect in the plenary and other sessions today.

June 2, 2019

Going beyond PARP inhibitors to improve cancer outcomes

We've heard much about PARP inhibitors but they aren't the only targets in DDR we can hit...

April 11, 2019

Picking PARP inhibitors apart

Are the PARPi a class effect or are there real differences between them that may become more apparent in future combo studies?

August 1, 2018

An under-appreciated oncology drug class

How can we improve on monotherapy with PARP inhibitors? How do we address primary and acquired resistance?

April 10, 2018

Going beyond PARP monotherapies

A look at PARP as it journeys from 1999 to 2017 culminating in a plenary presentation at ASCO

June 13, 2017

Going Beyond PARP in DNA Damage Repair

A look a one company's approach to DDR and potential combination opportunities in this niche

May 9, 2017

How do we get cancer immunotherapy to work in Prostate Cancer?

A candid look at new approaches being explored in cold tumours using prostate cancer as an example

May 1, 2017

Journal Club – February 2017

A look at what we can learn from some recently published new papers in the oncology space.

February 9, 2017

How to improve response rates with targeted therapies in oncology

Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches

February 2, 2017

Where does rucaparib fit in ovarian cancer?

How does the rucaparib data at ESMO fit in the treatment paradigm and what's next for PARPi?

October 24, 2016

What do Myriad Genetics really think of the Niraparib data?

Following the dispute between Tesaro and Myriad on HRD testing, here's Myriad's perspective on the data presented

October 20, 2016

What Tesaro aren’t telling you about niraparib

What you need to know about the Tesaro niraparib ovarian cancer data presented at ESMO 2016.

October 8, 2016

Biomarin PARP inhibitor talazoparib shows promise in gBRCA Breast Cancer

Biomarin have a good shot on goal with their PARP inhibitor talazoparib in gBRCA breast cancer

January 9, 2015

ASCO 2014 What do oncologists think of PARP inhibitors?

With the intense focus on immino-oncology, are targeted agents passe now?

June 11, 2014

AbbVie’s PARP inhibitor veliparib is highly active in triple negative breast cancer

The first readout from the I-SPY2 neoadjuvant breast cancer trial comes from the veliparib (PARP) arm.

December 13, 2013